Published in J Urol on July 01, 1978
The effects of testosterone on the cavernous tissue and erectile function. World J Urol (1997) 0.91
Micropenis: etiology, diagnosis and treatment approaches. J Clin Res Pediatr Endocrinol (2013) 0.83
Changes in amount and intracellular distribution of androgen receptor in human foreskin as a function of age. J Clin Invest (1987) 0.76
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
Identification of human T and B lymphocytes in normal peripheral blood and in chronic lymphocytic leukaemia. Lancet (1971) 7.25
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med (1992) 7.16
Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol (1977) 6.82
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA (1992) 6.40
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma? Lancet (1981) 4.28
Impotence following radical prostatectomy: insight into etiology and prevention. J Urol (1982) 4.08
Gestational diabetes mellitus--management guidelines. The Australasian Diabetes in Pregnancy Society. Med J Aust (1998) 4.05
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology (2001) 3.99
Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med (1996) 3.94
Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem (1994) 3.87
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem (1968) 3.54
Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate (1983) 3.53
Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A (1992) 3.28
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature (1988) 3.22
Peer review and publication. Presidential address before the 70th annual meeting of the American Society for Clinical Investigation, San Francisco, California, 30 April 1978. J Clin Invest (1978) 3.12
GROWTH OF YOUNG WHEAT PLANTS IN AUTO-IRRIGATED SOILS, AS RELATED TO THE WATER-SUPPLYING POWER OF THE SOIL AND TO THE ADJUSTMENT OF THE AUTO-IRRIGATOR. Plant Physiol (1926) 2.91
Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters. Ann Intern Med (1993) 2.77
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med (1990) 2.67
Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A (1989) 2.49
Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer (1993) 2.40
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet (1994) 2.35
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med (1974) 2.27
Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest (1970) 2.23
High resolution scanning electron microscopy of the nuclear envelope: demonstration of a new, regular, fibrous lattice attached to the baskets of the nucleoplasmic face of the nuclear pores. J Cell Biol (1992) 2.16
The nucleoporin Nup153 is required for nuclear pore basket formation, nuclear pore complex anchoring and import of a subset of nuclear proteins. EMBO J (2001) 2.14
Respiratory tract deposition of ultrafine particles in subjects with obstructive or restrictive lung disease. Chest (1990) 2.12
Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am (1997) 2.07
Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol (1978) 2.07
Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene (1997) 2.06
The syndromes of androgen resistance. N Engl J Med (1980) 2.05
Opportunities for medical research in the 21st century. JAMA (2001) 2.01
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. Lab Invest (1984) 1.99
The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem (1968) 1.98
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
The pathogenesis of benign prostatic hyperplasia. Am J Med (1980) 1.97
Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res (1993) 1.96
Antinuclear antibodies in patients receiving non-practolol beta-blockers. Br Med J (1978) 1.91
Formation of bone and cartilage by marrow stromal cells in diffusion chambers in vivo. Clin Orthop Relat Res (1980) 1.91
The hormonal control of sexual development. Science (1981) 1.88
Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. Crit Care Med (1996) 1.86
Regulation of cholesterol metabolism. I. N Engl J Med (1970) 1.86
Vesicovaginal and ureterovaginal fistulas: a summary of 25 years of experience. J Urol (1980) 1.84
Congenital absence of the vagina. The Mayer-Rokitansky-Kuster-Hauser syndrome. Ann Intern Med (1976) 1.81
Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol (1988) 1.81
Isolation and characterisation of a bipotential haematopoietic cell line. Nature (1979) 1.80
The conversion of testosterone to 5 alpha-androstan-17 beta-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest (1969) 1.75
The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol (1982) 1.70
Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol (1998) 1.69
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
Genetic susceptibility of benign prostatic hyperplasia. J Urol (1994) 1.66
Dimples, pores, star-rings, and thin rings on growing nuclear envelopes: evidence for structural intermediates in nuclear pore complex assembly. J Cell Sci (1997) 1.66
Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987. J Urol (1990) 1.65
Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci (1992) 1.65
Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology (1990) 1.64
Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol (1984) 1.63
Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles. J Urol (1991) 1.63
An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol (1979) 1.63
Cystic lesions of the prostate gland. A sonographic--pathologic correlation. J Ultrasound Med (1990) 1.61
Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol Cell Endocrinol (1992) 1.60
Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol (1998) 1.60
Steroid 5 alpha-reductase 2 deficiency. Endocr Rev (1993) 1.60
Studies on the influence of dietary cholesterol on cholesterol metabolism in the isotopic steady state in man. J Clin Invest (1965) 1.59
Testosterone formation and metabolism during male sexual differentiation in the human embryo. J Clin Endocrinol Metab (1974) 1.59
Precise localization of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis. J Urol (1985) 1.58
Cavernous nerve grafts restore erectile function in denervated rats. J Urol (1991) 1.57
The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combined immunodeficiency, SCIDX1. Hum Mol Genet (1993) 1.57
Ultrastructure of cell loss in intestinal mucosa. J Ultrastruct Res (1977) 1.56
Dihydrotestosterone binding by cultured human fibroblasts. Comparison of cells from control subjects and from patients with hereditary male pseudohermaphroditism due to androgen resistance. J Clin Invest (1976) 1.55
Cancer control following anatomical radical prostatectomy: an interim report. J Urol (1991) 1.55
Bile salt and micellar fat concentration in proximal small bowel contents of ileectomy patients. J Clin Invest (1968) 1.53
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
On the Pathology of Bullous Keratitis. Trans Am Ophthalmol Soc (1932) 1.53
Idiopathic retroperitoneal fibrosis. J Urol (1979) 1.53
The use and misuse of androgens. Metabolism (1980) 1.52